相关实验视频
Updated: Jul 14, 2025

07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
174
在患有类风湿性关节炎的患者中,JAK/STAT抑制会改变ILC1免疫反应
Marianna Lo Pizzo1, Lidia La Barbera2, Chiara Rizzo2
1Biomedicine, Neuroscience and Advanced Diagnostic, University of Palermo, Italy.
Clinical and experimental rheumatology
|October 9, 2023
概括
托法西替尼治疗减少了风湿性关节炎 (RA) 患者的先天性淋巴细胞 (ILC) 频率和IFN-γ产生. 这项研究研究了托法西提尼布.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 类风湿性关节炎 (RA) 的发病可能涉及先天性淋巴细胞 (ILC).
- 风险较高的人群显示ILC1的频率增加.
- 对于ILC1和ILC3的差异化,JAK3信号传输至关重要.
研究的目的:
- 评估托法西提尼布对RA患者ILCs的ex vivo影响.
- 确定ILC1和ILC3细胞是否是RA中托法西替尼治疗的特定点.
主要方法:
- 从RA患者的外周血液单核细胞 (PBMCs) (在托法西替尼或抗TNFα) 进行了治疗前和后的分析.
- 流细胞计评估了ILC1和ILC3的频率和细胞因子的产生 (IFN-γ,IL-17).
- 在体外研究中评估了托法西提尼布对ILCs的剂量依赖作用.
主要成果:
- RA 患者表现出扩大的 ILC1 种群.
- 托法西替尼治疗与抗TNFα不同,在三个月后显著降低了整体ILC频率和ILC1IFN-γ产生.
- 在体外托法西替尼治疗显示,ILC频率的剂量依赖性下降.
结论:
- 托法西提尼布调节了RA的先天免疫反应.
- 该药物有效地降低了ILC1细胞的频率及其IFN-γ的产生.
- 在RA患者中,ILC1细胞是托法西替尼的标.
相关概念视频
T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
Inflammatory Response
2.1K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
2.1K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
154
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
154
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
178
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
178

